Roche Reports Strong Q3 Sales Growth Amid COVID-19 Decline

In a recent report, Roche Group announced a 6% rise in Q3 sales and a 2% increase for the first nine months of 2024. The pharmaceutical giant attributes growth to high demand for innovative medicines, despite a drop in COVID-19 related sales. Earnings per share growth is also anticipated.

Date: 23-10-2024

AI Rating: 7

Roche Group's recent report demonstrates a positive performance with a 6% increase in Group sales for Q3, compared to last year, and a 2% increase for the first nine months. At constant exchange rates (CER), the sales growth was even more impressive at 9% for Q3 and 6% for the first nine months.

The pharmaceuticals division also saw a growth of 7% in CER sales, with significant contributions from several key products, indicating strong demand and a solid market position despite facing challenges such as COVID-19-related sales declines and market saturation from biosimilars and generics.

The report indicates a continuing trend of mid single-digit sales growth expected for fiscal 2024, and a promising outlook for core earnings per share, projected to grow in the high single-digit range. This reflects positively on the firm's profitability and overall financial health.

Additionally, Roche plans to increase its dividend in Swiss francs, signaling confidence in its financial stability and return on equity for shareholders.

Stocks: RHHBY